MCID: BLM007
MIFTS: 53

Bulimia Nervosa 1

Categories: Mental diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa 1

MalaCards integrated aliases for Bulimia Nervosa 1:

Name: Bulimia Nervosa 1 53 28
Bulimia Nervosa 53 12 72 51 14 69
Bulimia Nervosa, Susceptibility to 53 13
Bulimia 41 69
Bulimia Nervosa, Susceptibility to, 1 53
Binge Eating Disorder 69
Hyperorexia Nervosa 12
Buln1 53
Bn 53

Characteristics:

OMIM:

53
Inheritance:
multifactorial


HPO:

31
bulimia nervosa 1:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 53 607499
Disease Ontology 12 DOID:12129
ICD10 32 F50.2
MeSH 41 D002032
NCIt 46 C97162
MedGen 39 C1843776

Summaries for Bulimia Nervosa 1

Disease Ontology : 12 An eating disorder characterized by the restraining of food intake for a period of time followed by an over intake or binging period that results in feelings of guilt and low self-esteem.

MalaCards based summary : Bulimia Nervosa 1, also known as bulimia nervosa, is related to bulimia nervosa 2 and anorexia nervosa 1, and has symptoms including bulimia, decrease in appetite and symptoms. An important gene associated with Bulimia Nervosa 1 is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian rythm related genes. The drugs Dopamine and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include skin, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 72 Bulimia nervosa, also known as simply bulimia, is an eating disorder characterized by binge eating... more...

Description from OMIM: 607499

Related Diseases for Bulimia Nervosa 1

Diseases in the Bulimia Nervosa 1 family:

Bulimia Nervosa 2

Diseases related to Bulimia Nervosa 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 2 30.4 BDNF CCK COMT GHRL HTR2A LEP
2 anorexia nervosa 1 11.1
3 ataxia - hypogonadism - choroidal dystrophy 10.9
4 duodenogastric reflux 10.4 CCK PYY
5 stereotypic movement disorder 10.4 CCK NPY
6 alzheimer disease 5 10.3 HTR2A SLC6A4
7 gastroesophageal reflux 10.3 CCK GHRL PYY
8 abdominal obesity-metabolic syndrome 1 10.2 GHRL LEP
9 gastrointestinal system disease 10.2 CCK GHRL PYY
10 gastroparesis 10.2 CCK GHRL HTR3A
11 carcinoid syndrome 10.2 HTR3A NPY PYY
12 celiac disease 1 10.2 CCK GHRL PYY
13 alcoholic psychosis 10.2 HTR2A SLC6A4
14 rumination disorder 10.2 HTR3A HTR7
15 gilles de la tourette syndrome 10.2 BDNF COMT HTR3A
16 tardive dyskinesia 10.1 COMT HTR2A
17 periodic limb movement disorder 10.1 HTR2A SLC6A4
18 constipation 10.1 CCK HTR3A PYY SLC6A4
19 bruxism 10.1 HTR2A SLC6A4
20 phobia, specific 10.1 COMT MAOA
21 amnestic disorder 10.1 BDNF HTR3A HTR7
22 coronary artery vasospasm 10.1 HTR2A HTR7
23 dyspepsia 10.1 CCK GHRL HTR3A SLC6A4
24 central nervous system disease 10.1 BDNF HTR2A SLC6A4
25 intermittent explosive disorder 10.0 HTR7 NPY SLC6A4
26 functional diarrhea 10.0 GHRL HTR3A HTR7
27 central sleep apnea 10.0 LEP NPPB
28 psychosexual disorder 10.0 HTR2A HTR7 SLC6A4
29 motion sickness 10.0 HTR3A HTR7
30 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
31 extrinsic allergic alveolitis 10.0
32 pancreatic steatorrhea 10.0 CCK GHRL
33 phobic disorder 9.9 COMT MAOA SLC6A4
34 oppositional defiant disorder 9.9 COMT MAOA SLC6A4
35 bipolar i disorder 9.9 BDNF COMT HTR2A SLC6A4
36 antisocial personality disorder 9.9 COMT MAOA SLC6A4
37 schizoaffective disorder 9.9 BDNF COMT HTR2A SLC6A4
38 chronic pulmonary heart disease 9.9 HTR7 SLC6A4
39 conduct disorder 9.9 COMT MAOA SLC6A4
40 chronic fatigue syndrome 9.9 COMT MAOA SLC6A4
41 irritable bowel syndrome 9.9 CCK HTR3A HTR7 SLC6A4
42 functional gastric disease 9.9 CCK GHRL HTR3A HTR7
43 pathological gambling 9.9 HTR2A MAOA SLC6A4
44 atypical depressive disorder 9.9 HTR7 MAOA SLC6A4
45 toxic myocarditis 9.8 NPPB NPY
46 acquired metabolic disease 9.8 GHRL LEP MC4R NPY
47 social phobia 9.8 CCK HTR3A MAOA SLC6A4
48 kleptomania 9.8 HTR7 MAOA SLC6A4
49 narcolepsy 9.8 COMT GHRL HTR2A LEP
50 postpartum depression 9.8 BDNF COMT MAOA SLC6A4

Graphical network of the top 20 diseases related to Bulimia Nervosa 1:



Diseases related to Bulimia Nervosa 1

Symptoms & Phenotypes for Bulimia Nervosa 1

Symptoms via clinical synopsis from OMIM:

53
Neurologic Behavioral Psychiatric Manifestations:
recurrent episodes of binge eating
recurrent inappropriate conpensatory behavior to prevent weight gain, including self-induced vomiting, laxative or diuretic abuse, fasting, excessive exercise
overconcern with weight and body shape
feelings of guilt associated with episodes


Clinical features from OMIM:

607499

Human phenotypes related to Bulimia Nervosa 1:

31
# Description HPO Frequency HPO Source Accession
1 bulimia 31 HP:0100739

UMLS symptoms related to Bulimia Nervosa 1:


decrease in appetite, symptoms, salt craving

MGI Mouse Phenotypes related to Bulimia Nervosa 1:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 MC4R COMT NPY GHRL PYY HTR1B
2 endocrine/exocrine gland MP:0005379 9.81 CCK COMT GHRL HTR1B HTR2A SLC6A4
3 adipose tissue MP:0005375 9.8 MC4R NPY GHRL HTR1B PYY LEP
4 homeostasis/metabolism MP:0005376 9.73 MAOA MC4R COMT GHRL NPY PYY
5 nervous system MP:0003631 9.36 MC4R COMT NPY PYY SLC6A4 HTR3A

Drugs & Therapeutics for Bulimia Nervosa 1

Drugs for Bulimia Nervosa 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97240-79-4 5284627
3
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
5
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
6
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
7
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
8
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
9
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
10 Raclopride Investigational Phase 4 84225-95-6
11 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
12 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Anti-Obesity Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Adrenergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
22 Antipsychotic Agents Phase 4,Not Applicable
23 Autonomic Agents Phase 4,Phase 2,Phase 1,Not Applicable
24 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
25 Dopamine Antagonists Phase 4
26 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
27 Tranquilizing Agents Phase 4,Phase 2,Not Applicable
28 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Appetite Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Not Applicable
31 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
33 Hypoglycemic Agents Phase 4,Phase 3
34 Incretins Phase 4,Phase 3
35 Atomoxetine Hydrochloride Phase 4
36 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
37 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Not Applicable
38 Excitatory Amino Acids Phase 4,Phase 3,Not Applicable
39 Adrenergic Agonists Phase 4
40 Adrenergic alpha-Agonists Phase 4
41
Serotonin Phase 4,Phase 2,Not Applicable 50-67-9 5202
42 Serotonin Agents Phase 4,Phase 2,Not Applicable
43 Serotonin Uptake Inhibitors Phase 4,Phase 2,Not Applicable
44 Vasoconstrictor Agents Phase 4
45 Analgesics Phase 4
46 Duloxetine Hydrochloride Phase 4
47 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
48 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Not Applicable
49 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 197)

# Name Status NCT ID Phase Drugs
1 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
2 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
3 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
4 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
5 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
6 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
7 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
8 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
9 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
10 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
11 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
12 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
13 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
14 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
15 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
16 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
17 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
18 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
19 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
20 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
21 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
22 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
23 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
24 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
25 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
26 Craving, Binge Eating and Obesity Completed NCT00414167 Phase 2, Phase 3 bupropion
27 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
28 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
29 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
30 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
31 Healthy Approach to weIght Management and Food in Eating Disorders (HAPIFED) Recruiting NCT02464345 Phase 2, Phase 3
32 Binge Eating Liraglutide Intervention Recruiting NCT03279731 Phase 3 Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml;Placebo
33 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment Recruiting NCT03045341 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
34 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Active, not recruiting NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
35 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Enrolling by invitation NCT03063606 Phase 2, Phase 3 NB Medication (on-going from acute treatment)
36 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy Enrolling by invitation NCT03047005 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
37 Dasotraline Binge Eating Disorder Extension Study Enrolling by invitation NCT02684279 Phase 3 Dasotraline
38 N-acetylcysteine in the Treatment of Bulimia Nervosa Terminated NCT01033149 Phase 3 N-acetylcysteine
39 N-acetylcysteine in Bulimia Nervosa Terminated NCT01131572 Phase 2, Phase 3 N-acetylcysteine NAC
40 Pramipexole for Binge Eating Disorder Withdrawn NCT01106053 Phase 3 Pramipexole
41 Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects Unknown status NCT02659488 Phase 2 Lisdexamfetamine
42 The Effect of Electroacupuncture on Obesity Unknown status NCT01102075 Phase 2
43 Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Completed NCT00304187 Phase 2 Erythromycin;Placebo
44 Family Therapy for Adolescent Bulimia Nervosa Completed NCT00518843 Phase 2
45 Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Completed NCT00522769 Phase 1, Phase 2
46 Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa Completed NCT00494858 Phase 2
47 Psychological Treatment of Overweight Binge Eaters Completed NCT01208272 Phase 1, Phase 2
48 The Psychological Treatment of Overweight Binge Eaters Minority Supplement Completed NCT01208259 Phase 1, Phase 2
49 Binge Eating and Chromium Study Completed NCT00904306 Phase 1, Phase 2
50 Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals Completed NCT00300742 Phase 2 Topiramate

Search NIH Clinical Center for Bulimia Nervosa 1

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: bulimia

Genetic Tests for Bulimia Nervosa 1

Genetic tests related to Bulimia Nervosa 1:

# Genetic test Affiliating Genes
1 Bulimia Nervosa 1 28 BDNF

Anatomical Context for Bulimia Nervosa 1

MalaCards organs/tissues related to Bulimia Nervosa 1:

38
Skin

Publications for Bulimia Nervosa 1

Articles related to Bulimia Nervosa 1:

(show top 50) (show all 707)
# Title Authors Year
1
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. ( 29407005 )
2018
2
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
3
The Impact of Alexithymia on Emotion Dysregulation in Anorexia Nervosa and Bulimia Nervosa over Time. ( 29266572 )
2018
4
Impulsivity and test meal intake among women with bulimia nervosa. ( 28077307 )
2017
5
Anorexia nervosa and bulimia nervosa: A meta-analysis of executive functioning. ( 28851577 )
2017
6
Reduced Inferior and Orbital Frontal Thickness in Adolescent Bulimia Nervosa Persists Over Two-Year Follow-Up. ( 28942809 )
2017
7
Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness. ( 28762842 )
2017
8
Visual selective attention in body dysmorphic disorder, bulimia nervosa and healthy controls. ( 27998509 )
2017
9
Risk of being convicted of theft and other crimes in anorexia nervosa and bulimia nervosa: A prospective cohort study in a Swedish female population. ( 28791709 )
2017
10
Associations of borderline personality disorder traits with stressful events and emotional reactivity in women with bulimia nervosa. ( 28691843 )
2017
11
A Randomised Controlled Comparison of Second-Level Treatment Approaches for Treatment-Resistant Adults with Bulimia Nervosa and Binge Eating Disorder: Assessing the Benefits of Virtual Reality Cue Exposure Therapy. ( 28804985 )
2017
12
Psychodynamic psychotherapies for bulimia nervosa: trend and perspectives. ( 28755083 )
2017
13
Computerized assessment of body image in anorexia nervosa and bulimia nervosa: comparison with standardized body image assessment tool. ( 27796596 )
2017
14
CBT4BN: A Randomized Controlled Trial of Online Chat and Face-to-Face Group Therapy for Bulimia Nervosa. ( 27883997 )
2017
15
The relevance of personality traits in impulsivity-related disorders: From substance use disorders and gambling disorder to bulimia nervosa. ( 28838248 )
2017
16
The impact of acute stress on the neural processing of food cues in bulimia nervosa: Replication in two samples. ( 28691844 )
2017
17
Severity of bulimia nervosa and its impact on treatment outcome. ( 28744624 )
2017
18
Rapid improvements in emotion regulation predict intensive treatment outcome for patients with bulimia nervosa and purging disorder. ( 28833314 )
2017
19
Response to the best available treatment for bulimia nervosa and binge-eating disorder is disease severity-dependent. ( 28707477 )
2017
20
Response in taste circuitry is not modulated by hunger and satiety in women remitted from bulimia nervosa. ( 28691842 )
2017
21
Depictive and metric body size estimation in anorexia nervosa and bulimia nervosa: A systematic review and meta-analysis. ( 28818670 )
2017
22
Altered intrinsic functional brain architecture in female patients with bulimia nervosa. ( 28949286 )
2017
23
Influence of TFAP2B and KCTD15 genetic variability on personality dimensions in anorexia and bulimia nervosa. ( 28948079 )
2017
24
Psychotherapy for bulimia nervosa on symptoms of depression: A meta-analysis of randomized controlled trials. ( 28804915 )
2017
25
Oral health considerations in anorexia and bulimia nervosa. 2. Multidisciplinary management and personalized dental care. ( 28862585 )
2017
26
Virtual Reality as a Promising Strategy in the Assessment and Treatment of Bulimia Nervosa and Binge Eating Disorder: A Systematic Review. ( 28698483 )
2017
27
Web-Based Aftercare for Women With Bulimia Nervosa Following Inpatient Treatment: Randomized Controlled Efficacy Trial. ( 28939544 )
2017
28
Hypovitaminosis D3, Leukopenia, and Human Serotonin Transporter Polymorphism in Anorexia Nervosa and Bulimia Nervosa. ( 26903713 )
2016
29
Executive Functioning and Visuospatial Abilities in Bulimia Nervosa with or without a Previous History of Anorexia Nervosa. ( 26708940 )
2016
30
Does habituation really happen? Investigation of psycho-biological responses to body exposure in bulimia nervosa. ( 28027485 )
2016
31
Cue-exposure software for the treatment of bulimia nervosa and binge eating disorder. ( 27776602 )
2016
32
Neural signature of behavioural inhibition in women with bulimia nervosa. ( 27575858 )
2016
33
Examining the relationship between selective attentional bias for food- and body-related stimuli and purging behaviour in bulimia nervosa. ( 27507132 )
2016
34
Altered structural and effective connectivity in anorexia and bulimia nervosa in circuits that regulate energy and reward homeostasis. ( 27801897 )
2016
35
Implicit learning on a probabilistic classification task in adults and adolescents with Bulimia Nervosa. ( 26978183 )
2016
36
Testing the DSM-5 severity indicator for bulimia nervosa in a treatment-seeking sample. ( 27650858 )
2016
37
A latent profile analysis of childhood trauma in women with bulimia nervosa: Associations with borderline personality disorder psychopathology. ( 27038436 )
2016
38
Impulsivity-related traits distinguish women with co-occurring bulimia nervosa in a psychiatric sample. ( 27567004 )
2016
39
Recovery From Anorexia Nervosa and Bulimia Nervosa at 22-Year Follow-Up. ( 28002660 )
2016
40
Increased use of antimicrobial medication in bulimia nervosa and binge eating disorder prior to the eating disorder treatment. ( 26875554 )
2016
41
An examination of affect prior to and following episodes of getting drunk in women with bulimia nervosa. ( 27111214 )
2016
42
How useful is the DSM-5 severity indicator in bulimia nervosa? A clinical study including a measure of impairment. ( 27788453 )
2016
43
The ABBA study - approach bias modification in bulimia nervosa and binge eating disorder: study protocol for a randomised controlled trial. ( 27670138 )
2016
44
Psychoanalytic psychotherapy with a client with bulimia nervosa. ( 27267505 )
2016
45
Validity and clinical utility of the DSM-5 severity specifier for bulimia nervosa: results from a multisite sample of patients who received evidence-based treatment. ( 27435722 )
2016
46
Smoking status and psychosocial factors in binge eating disorder and bulimia nervosa. ( 26741260 )
2016
47
A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. ( 26942768 )
2016
48
Meta-analysis of theory of mind in anorexia nervosa and bulimia nervosa: A specific A^mpairment of cognitive perspective taking in anorexia nervosa? ( 27425037 )
2016
49
Mood spectrum comorbidity in patients with anorexia and bulimia nervosa. ( 27766498 )
2016
50
Personality psychopathology differentiates risky behaviors among women with bulimia nervosa. ( 27301347 )
2016

Variations for Bulimia Nervosa 1

Expression for Bulimia Nervosa 1

Search GEO for disease gene expression data for Bulimia Nervosa 1.

Pathways for Bulimia Nervosa 1

Pathways related to Bulimia Nervosa 1 according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 CCK GHRL HTR1B HTR2A HTR7 LEP
3
Show member pathways
11.97 BDNF GHRL HTR1B NPY
4 11.77 BDNF HTR2A HTR3A MAOA SLC6A4
5
Show member pathways
11.71 HTR1B HTR2A HTR7
6 11.49 HTR1B HTR2A HTR3A HTR7 MAOA SLC6A4
7 10.87 NPY PYY
8
Show member pathways
10.85 COMT MAOA SLC6A4
9
Show member pathways
10.84 COMT MAOA
10
Show member pathways
10.63 COMT MAOA
11 10.58 COMT MAOA
12 10.55 HTR1B HTR2A HTR3A HTR7 MAOA SLC6A4

GO Terms for Bulimia Nervosa 1

Cellular components related to Bulimia Nervosa 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 CCK COMT GHRL HTR2A HTR3A

Biological processes related to Bulimia Nervosa 1 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.97 CCK GHRL HTR1B HTR2A HTR7 MC4R
2 response to drug GO:0042493 9.91 COMT HTR1B HTR2A SLC6A4
3 chemical synaptic transmission GO:0007268 9.8 HTR1B HTR2A HTR3A HTR7 NPY
4 response to ethanol GO:0045471 9.79 HTR1B HTR3A LEP
5 circadian rhythm GO:0007623 9.76 HTR7 LEP SLC6A4
6 regulation of blood pressure GO:0008217 9.69 LEP NPPB NPY
7 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 HTR1B HTR7 NPY
8 eating behavior GO:0042755 9.64 CCK LEP
9 regulation of dopamine secretion GO:0014059 9.63 HTR1B HTR2A
10 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.63 HTR1B HTR2A
11 smooth muscle contraction GO:0006939 9.62 HTR2A HTR7
12 energy reserve metabolic process GO:0006112 9.61 LEP MC4R
13 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.6 HTR1B HTR2A
14 central nervous system neuron development GO:0021954 9.59 LEP NPY
15 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
16 catecholamine metabolic process GO:0006584 9.57 COMT MAOA
17 regulation of appetite GO:0032098 9.56 NPY PYY
18 negative regulation of appetite GO:0032099 9.55 CCK LEP
19 regulation of behavior GO:0050795 9.54 HTR1B HTR2A
20 dopamine catabolic process GO:0042420 9.52 COMT MAOA
21 vasoconstriction GO:0042310 9.5 HTR1B HTR7 SLC6A4
22 regulation of metabolic process GO:0019222 9.49 LEP MC4R
23 positive regulation of appetite GO:0032100 9.46 GHRL NPY
24 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.43 HTR1B HTR7
25 behavior GO:0007610 9.43 HTR1B HTR2A NPY
26 adult feeding behavior GO:0008343 9.33 GHRL LEP NPY
27 feeding behavior GO:0007631 9.26 HTR1B MC4R NPY PYY
28 regulation of receptor activity GO:0010469 9.17 BDNF CCK GHRL LEP NPPB NPY

Molecular functions related to Bulimia Nervosa 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor binding GO:0001664 9.54 GHRL NPY PYY
2 neuropeptide hormone activity GO:0005184 9.5 CCK NPY PYY
3 neurotransmitter receptor activity GO:0030594 9.43 HTR1B HTR2A HTR7
4 G-protein coupled serotonin receptor activity GO:0004993 9.33 HTR1B HTR2A HTR7
5 serotonin binding GO:0051378 9.26 HTR1B HTR2A HTR3A HTR7
6 hormone activity GO:0005179 9.1 CCK GHRL LEP NPPB NPY PYY

Sources for Bulimia Nervosa 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....